Malignant Lung Neoplasm — Trials

Malignant Lung Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

11,127 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,650
Recruiting: 1,433
Ph III recruiting: 179
Growth YoY: +7.6%
Industry share: 37%
Top sponsor: AstraZeneca
Termination share: 34.8%
Trials / 1,000 deaths: 20.1 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,491)

clinicaltrialsPublishedShowing 551–600 of 1,856 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07355205	First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer(FLINN)	recruiting	Phase 1 / Phase 2	26	Washington University School of MedicineOTHER	1	Jul 10, 2026	clinicaltrials
NCT07452224	ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer	recruiting	Phase 2	80	iLeukon Therapeutics, Inc.INDUSTRY	1	Jul 10, 2026